Recent research indicates that Paxlovid's effectiveness in reducing COVID-19 hospitalizations and mortality for older vaccinated adults may be overstated. A study involving nearly 1.5 million Canadians found no significant benefits from Paxlovid for this demographic, contradicting initial claims by Pfizer which had reported an 89% reduction in hospitalizations and deaths among unvaccinated middle-aged individuals. This raises questions about the generalizability of Paxlovid's purported benefits, as vaccination status significantly alters the risk and response in older populations.
Our main finding was that among vaccinated older adults, Paxlovid showed no statistically significant reduction in COVID-19 hospitalizations or on mortality, says Mafi.
But the group they studied was mostly middle-aged and unvaccinated, which is a much different population than exists today.
The 2022 Pfizer study was and continues to be used to support the assumption that the benefits of Paxlovid in unvaccinated adults also apply to vaccinated adults.
Collection
[
|
...
]